Innate Pharma SA
PAR:IPH
Innate Pharma SA
PAR:IPH
Price:
1.25
EUR
-1.73%
Market Closed
Market Cap:
€117.2m
Balance Sheet
Balance Sheet Decomposition
Innate Pharma SA
Innate Pharma SA
Balance Sheet Decomposition is not available for
Innate Pharma SA
Innate Pharma SA
Balance Sheet
Innate Pharma SA
Innate Pharma SA
Currency: EUR
| Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
11
|
46
|
32
|
47
|
31
|
38
|
150
|
153
|
176
|
99
|
152
|
203
|
137
|
104
|
84
|
71
|
66
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
11
|
9
|
25
|
150
|
150
|
176
|
99
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
11
|
45
|
30
|
36
|
22
|
13
|
0
|
3
|
0
|
0
|
152
|
203
|
137
|
104
|
84
|
71
|
66
|
|
| Short-Term Investments |
0
|
14
|
16
|
55
|
48
|
23
|
3
|
3
|
0
|
2
|
3
|
22
|
0
|
22
|
17
|
15
|
16
|
15
|
16
|
17
|
22
|
14
|
|
| Total Receivables |
2
|
1
|
3
|
4
|
5
|
18
|
6
|
5
|
6
|
7
|
7
|
26
|
0
|
26
|
14
|
128
|
6
|
14
|
13
|
31
|
46
|
2
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
3
|
2
|
14
|
0
|
14
|
0
|
3
|
3
|
11
|
1
|
3
|
15
|
1
|
|
| Other Receivables |
2
|
1
|
3
|
0
|
0
|
0
|
5
|
5
|
4
|
5
|
5
|
11
|
0
|
11
|
14
|
125
|
3
|
3
|
13
|
28
|
31
|
1
|
|
| Other Current Assets |
15
|
11
|
3
|
5
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
6
|
0
|
7
|
7
|
24
|
13
|
8
|
5
|
7
|
9
|
3
|
|
| Total Current Assets |
17
|
27
|
21
|
64
|
56
|
52
|
56
|
41
|
53
|
41
|
49
|
230
|
0
|
230
|
138
|
320
|
238
|
173
|
138
|
140
|
148
|
86
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
2
|
9
|
8
|
7
|
6
|
7
|
6
|
9
|
0
|
9
|
11
|
10
|
12
|
12
|
10
|
9
|
6
|
5
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
0
|
9
|
46
|
85
|
97
|
46
|
44
|
2
|
0
|
0
|
|
| Note Receivable |
2
|
3
|
3
|
4
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
17
|
30
|
30
|
14
|
11
|
10
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
60
|
35
|
37
|
39
|
40
|
35
|
10
|
10
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
33
|
0
|
33
|
0
|
2
|
1
|
7
|
5
|
9
|
9
|
0
|
|
| Total Assets |
20
N/A
|
30
+53%
|
25
-18%
|
69
+179%
|
63
-9%
|
61
-4%
|
64
+5%
|
48
-25%
|
60
+25%
|
48
-20%
|
56
+16%
|
282
+404%
|
0
N/A
|
282
N/A
|
255
-9%
|
451
+77%
|
401
-11%
|
307
-23%
|
267
-13%
|
208
-22%
|
184
-11%
|
111
-40%
|
|
| Liabilities | |||||||||||||||||||||||
| Accounts Payable |
1
|
2
|
1
|
3
|
5
|
7
|
6
|
5
|
4
|
5
|
5
|
16
|
0
|
16
|
20
|
86
|
41
|
21
|
15
|
14
|
26
|
24
|
|
| Accrued Liabilities |
0
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
3
|
0
|
4
|
4
|
6
|
7
|
8
|
7
|
6
|
7
|
7
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
21
|
2
|
7
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
2
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
2
|
2
|
31
|
2
|
9
|
9
|
|
| Other Current Liabilities |
1
|
0
|
0
|
5
|
3
|
3
|
1
|
0
|
8
|
8
|
1
|
55
|
0
|
55
|
48
|
83
|
50
|
12
|
20
|
20
|
15
|
9
|
|
| Total Current Liabilities |
2
|
2
|
2
|
10
|
11
|
13
|
9
|
7
|
16
|
15
|
9
|
76
|
0
|
76
|
74
|
197
|
122
|
45
|
80
|
41
|
40
|
33
|
|
| Long-Term Debt |
1
|
1
|
0
|
3
|
3
|
6
|
8
|
7
|
5
|
3
|
4
|
4
|
0
|
4
|
5
|
14
|
17
|
62
|
47
|
93
|
76
|
22
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
7
|
5
|
9
|
9
|
0
|
|
| Other Liabilities |
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
14
|
6
|
2
|
115
|
0
|
115
|
91
|
72
|
44
|
37
|
29
|
11
|
8
|
47
|
|
| Total Liabilities |
5
N/A
|
5
+2%
|
5
+2%
|
13
+174%
|
14
+5%
|
20
+44%
|
17
-12%
|
15
-15%
|
34
+131%
|
25
-26%
|
16
-37%
|
195
+1 153%
|
0
N/A
|
195
N/A
|
169
-13%
|
284
+68%
|
184
-35%
|
151
-18%
|
160
+6%
|
154
-4%
|
132
-14%
|
102
-23%
|
|
| Equity | |||||||||||||||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
3
|
0
|
3
|
3
|
3
|
4
|
4
|
4
|
4
|
4
|
4
|
|
| Retained Earnings |
9
|
14
|
20
|
26
|
35
|
44
|
63
|
77
|
84
|
87
|
90
|
104
|
0
|
104
|
152
|
136
|
156
|
220
|
272
|
329
|
336
|
386
|
|
| Additional Paid In Capital |
24
|
39
|
39
|
81
|
83
|
84
|
108
|
108
|
108
|
109
|
128
|
188
|
0
|
188
|
235
|
300
|
370
|
372
|
375
|
380
|
384
|
391
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
15
N/A
|
26
+70%
|
20
-22%
|
56
+181%
|
50
-12%
|
41
-17%
|
47
+14%
|
34
-29%
|
27
-21%
|
23
-12%
|
40
+72%
|
86
+114%
|
0
N/A
|
86
N/A
|
86
0%
|
167
+95%
|
217
+30%
|
156
-28%
|
107
-31%
|
54
-50%
|
52
-4%
|
9
-83%
|
|
| Total Liabilities & Equity |
20
N/A
|
30
+53%
|
25
-18%
|
69
+179%
|
63
-9%
|
61
-4%
|
64
+5%
|
48
-25%
|
60
+25%
|
48
-20%
|
56
+16%
|
282
+404%
|
0
N/A
|
282
N/A
|
255
-9%
|
451
+77%
|
401
-11%
|
307
-23%
|
267
-13%
|
208
-22%
|
184
-11%
|
111
-40%
|
|
| Shares Outstanding | |||||||||||||||||||||||
| Common Shares Outstanding |
25
|
25
|
25
|
25
|
25
|
26
|
37
|
38
|
38
|
38
|
46
|
54
|
0
|
54
|
54
|
58
|
79
|
79
|
80
|
80
|
81
|
84
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
